<DOC>
	<DOCNO>NCT00484939</DOCNO>
	<brief_summary>This 2-arm study assess efficacy safety bevacizumab ( Avastin ) combination capecitabine ( Xeloda ) , compare capecitabine alone , elderly patient metastatic colorectal cancer . Patients randomize receive either bevacizumab ( 7.5 mg/kg intravenously Day 1 3-week cycle ) combination capecitabine ( 1000 mg/m^2 orally twice day Days 1-14 3-week cycle ) capecitabine ( 1000 mg/m^2 orally twice day Days 1-14 3-week cycle ) alone . No notable trend interaction laboratory value , electrocardiogram , vital sign suggest effect either direction capecitabine/bevacizumab combination therapy capecitabine monotherapy observe study .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Combination With Capecitabine ( Xeloda ) Elderly Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient , ≥ 70 year age . Cancer colon rectum . Metastatic disease diagnose ≤ 6 month enrollment . ≥ 1 measurable metastatic lesion . Adjuvant antivascular endothelial growth factor ( VEGF ) treatment . Prior chemotherapeutic treatment metastatic colorectal cancer . Past current history malignancy ( exception basal squamous cell cancer skin , situ cancer cervix ) . Clinically significant cardiovascular disease . Current recent daily use aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory drug ( NSAID ) , full dose anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>